Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MELISSA
2024-514652-33-00Phase 2Withdrawn
- Sponsor
- European Myeloma Network
- Start
- Feb 2025
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of melphalan flufenamide in multiple myeloma (MM), sponsored by European Myeloma Network. Primary endpoint: Overall response rate (ORR). Planned start Feb 2025; status: withdrawn.
02
Drugs
melphalan flufenamide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514652-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514652-33-00.